MYGNHealthcare · Diagnostics & ResearchThe 10 Wall Street analysts covering Myriad Genetics, Inc. hold a median 12-month price target of $3.2 — -17.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 19 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Myriad Genetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MYGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −17.7% from it.
Of the 20 most recent actions, 0 moved their price target up and 7 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | UBS | Maintains | Neutral | $6.00 → $3.60 |
| 1 Sept 2026 | Piper Sandler | Downgrade | Underweight | — |
| 1 Sept 2026 | Piper Sandler | Downgrade | Underweight | $5.45 → $2.00 |
| 18 Aug 2026 | Stephens & Co. | Maintains | Equal-Weight | $5.00 → $3.00 |
| 18 Aug 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 3 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 3 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $5.50 → $3.00 |
| 31 July 2026 | TD Cowen | Maintains | Hold | — |
| 31 July 2026 | TD Cowen | Maintains | Hold | $6.00 → $4.00 |
| 6 May 2026 | TD Cowen | Maintains | Hold | $7.00 → $6.00 |
| 6 May 2026 | TD Cowen | Maintains | Hold | — |
| 6 May 2026 | Wells Fargo | Maintains | Equal-Weight | $6.00 → $5.50 |
| 6 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 24 Feb 2026 | UBS | Maintains | Neutral | — |
| 24 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
| 5 Nov 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 4 Nov 2025 | TD Cowen | Maintains | Hold | — |
| 4 Nov 2025 | UBS | Maintains | Neutral | — |
| 21 May 2025 | Scotiabank | Downgrade | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MYGN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Myriad Genetics, Inc. returned −49.3% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 83% of US stocks
Cheaper than 65% of US stocks
Cheaper than 86% of US stocks
Higher than 15% of US stocks
Higher than 26% of US stocks
Higher than 80% of US stocks
Higher than 21% of US stocks
Higher than 18% of US stocks
Higher than 26% of US stocks
Higher than 28% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Myriad Genetics, Inc. has a market value of $396.0M and an enterprise value of $491.3M.
Revenue in the twelve months to 30 June 2026: $806.6M. The latest quarter shrank 10.5% year on year.
Net income over the same four quarters: −$112.6M, a −14.0% net margin.
Diluted earnings per share, trailing twelve months: $−1.19.
Free cash flow in the twelve months to 30 June 2026: −$14.2M, after $21.9M of capital spending.
Trailing P/E: −1.0×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Myriad Genetics, Inc. employs 2,700 people — $299K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Myriad Genetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Myriad Genetics announced the promotion of Vishal Sikri to Executive Vice President - Commercial, effective September 16, 2026. Sikri will oversee the company's commercial operations.
Why it matters — This leadership appointment signals a change in the company's commercial management, which could influence how Myriad Genetics drives its business going forward.
Piper Sandler downgraded Myriad Genetics stock to Underweight, a rare double-downgrade, citing doubt about the company's path to sustainable profitability.
Why it matters — The downgrade signals growing questions about Myriad's ability to sustain profitable operations, which is central to investor confidence in the company.
Myriad Genetics announced that its management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on September 10, 2026, at 11:00am EST. The presentation will be available via a live audio webcast in the investor information section of Myriad's website.
Why it matters — The presentation gives Myriad Genetics watchers an opportunity to hear directly from management about the company's progress at a major industry conference.
A law firm, Kirby McInerney LLP, has announced an investigation into Myriad Genetics and its senior management regarding potential violations of federal securities laws. The investigation follows the company's July 30, 2026 report of an 11% year-over-year decline in second-quarter revenue.
Why it matters — This securities-law investigation adds legal risk and uncertainty for Myriad Genetics shareholders, particularly following the company's recent revenue decline.
Myriad Genetics reported Q2 2026 revenue of roughly $190.7 million, below the consensus estimate of $206-208 million, and cut its full-year revenue guidance by about $90 million while suspending adjusted EBITDA guidance. Levi & Korsinsky has launched an investigation into potential securities law violations on behalf of MYGN investors.
Why it matters — A revenue miss, a significant guidance cut, and a securities investigation could signal serious operational or disclosure issues for Myriad Genetics.
The 10 Wall Street analysts covering Myriad Genetics, Inc. have a median 12-month price target of $3.2, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Myriad Genetics, Inc., 1 rate it a Buy, 6 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Myriad Genetics, Inc. 45 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Myriad Genetics, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies -17.7% from the last close, and Ticker Nerd's factor model ranks Myriad Genetics, Inc. 45 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Myriad Genetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MYGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.
Myriad Genetics, Inc. returned -49.3% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Myriad Genetics Inc. is a molecular diagnostics and precision medicine company that develops genetic tests to support disease risk assessment, diagnosis, and treatment decisions.
The most recent item we track (GlobeNewsWire, 16 Sept 2026): "Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial". Myriad Genetics announced the promotion of Vishal Sikri to Executive Vice President - Commercial, effective September 16, 2026. Sikri will oversee the company's commercial operations.
Myriad Genetics Inc. is a molecular diagnostics and precision medicine company that develops genetic tests to support disease risk assessment, diagnosis, and treatment decisions. The company’s current portfolio spans oncology, women’s health, and pharmacogenomics, with products used for hereditary cancer risk evaluation, tumor profiling, companion diagnostics, reproductive health screening, prenatal testing, and medication-response insights. Its tests are designed for healthcare providers, hospitals, and health systems that use genetic and genomic information to inform patient care across specialties such as cancer, prenatal care, and mental health. Myriad Genetics also offers specialized services that help match patients with targeted therapies and support clinical decision-making through laboratory-based molecular analysis. Headquartered in Salt Lake City, Utah, Myriad Genetics plays an important role in the expanding field of genetic testing, where molecular insights are increasingly integrated into routine medical care.
CEO Mr. Samraat S. Raha · 2,700 employees · United States · https://www.myriad.com
